Cardiff Lexington Corp
CDIXOTCHealthcare · Services-Offices & Clinics of Doctors of Medicine · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $11.5M | $8.3M | $11.9M | $10.7M | $9.9M | $2.4M |
| Operating income | $1.1M | −$193,504 | $5.2M | $3.9M | $1.7M | −$4.3M |
| Net income | −$5.5M | −$3.3M | $3.0M | −$5.4M | $666,293 | −$6.3M |
| Total assets | $29.1M | $23.9M | $20.7M | $13.3M | $15.3M | $3.3M |
| Total liabilities | $26.0M | $16.3M | $14.1M | $10.2M | $11.4M | $8.2M |
| Equity | −$2.5M | $2.7M | $731,418 | −$1.7M | $486,840 | −$4.8M |
| EPS (diluted) | — | — | — | — | $-0.01 | — |
| Shares out. | 19.7M | 8.7M | 908.5M | 10,997 | 166.1M | 70.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 9.5%
- Net margin
- −47.7%
- Return on equity
- 223.0%
- Return on assets
- −18.9%
- Return on capital (ROCE)
- 33.8%
- Liabilities / assets
- 89.4%
- Debt / equity
- —
- Book value / share
- $-0.13
- Revenue growth (YoY)
- 39.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.49distress
- Accruals / assets
- −9.1%clean
- Beneish M-Score
- -2.68normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 3 warning● 4 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Qmissed a reporting deadline ↗May 24, 2023
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 12, 2021
- NT 10-Q/Amissed a reporting deadline ↗Aug 24, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Staley Louis Jack Sr.Director | Apr 1, 2026 | Grant | 5,000 | $0.00 |
| Pennington Catherine B.Director | Apr 1, 2026 | Grant | 5,000 | $0.00 |
| Johnson Gillard B. IiiDirector | Apr 1, 2026 | Grant | 5,000 | $0.00 |
| Cunningham Alex H.Officer — Chief Executive Officer | Jan 29, 2026 | J | 556,528 | $0.00 |
| Shafer Matthew TOfficer — Chief Financial Officer | Jan 13, 2026 | Grant | 62,500 | $0.00 |
| Thompson DanielOfficer — Chairman of the Board | Oct 25, 2024 | Conversion | 26,124 | $0.00 |
| Staley Louis Jack Sr.Director | Sep 26, 2025 | Grant | 5,000 | $0.00 |
| Shafer Matthew TOfficer — Chief Financial Officer | Nov 19, 2025 | Conversion | 10,000 | $0.00 |
| Pennington Catherine B.Director | Sep 26, 2025 | Grant | 5,000 | $0.00 |
| Johnson Gillard B. IiiDirector | Sep 26, 2025 | Grant | 5,000 | $0.00 |
| Cunningham Alex H.Officer — Chief Executive Officer | Apr 24, 2025 | Conversion | 1.1M | $0.00 |
| Cunningham Alex H.Officer — President and CEO | Oct 25, 2024 | Conversion | 12,500 | $2.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1,161 | 1.0 | +181.8% |
| Apr 30, 2026 | 412 | 1.0 | +1148.5% |
| Apr 15, 2026 | 33 | 1.0 | -95.0% |
| Mar 31, 2026 | 664 | 1.0 | +1912.1% |
| Mar 13, 2026 | 33 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Modified shareholder rights · Amended charter or bylawsFeb 3, 2026
- Director / officer changeJan 5, 2026
- Prior financials not reliable (restatement)Aug 14, 2025
- Modified shareholder rights · Amended charter or bylawsDec 4, 2024
- Prior financials not reliable (restatement)Oct 17, 2024
- Changed auditorSep 19, 2024
- Entered a material agreementJun 11, 2024
- Director / officer changeJun 10, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-Q FOR MAR 2026May 13, 2026
- AWFORM AWMay 12, 2026
- RWFORM RWApr 30, 2026
- 4Apr 3, 2026
- 4Apr 3, 2026
- 4Apr 3, 2026
- POS AMPOST-EFFECTIVE AMENDMENT 1Mar 13, 2026
- 10-KFORM 10-K FOR DEC 2025Mar 10, 2026
- EFFECTFeb 13, 2026
- S-1/AAMENDMENT NO .3Feb 5, 2026
- 8-KCURRENT REPORTFeb 3, 2026
- 4Feb 2, 2026
- S-1/AFORM S-1 AMENDMENT 2Jan 26, 2026
- S-1/AAMENDMENT NO. 1 TO FORM S-1Jan 20, 2026
- 4Jan 16, 2026